Cancer Stem Cell News 8.07 February 27, 2019 | |
![]() | |
| |
TOP STORYA Stemness Screen Reveals C3orf54/INKA1 as a Promoter of Human Leukemia Stem Cell Latency Investigators interrogated functionally-validated datasets of leukemia stem cell-specific genes together with their known protein interactors and selected 64 candidates for a competitive in vivo gain-of-function screen to identify genes that enhanced stemness in human cord blood hematopoietic stem and progenitor cells. [Blood] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists demonstrated that radiation-induced senescent glioblastoma cells exhibited a senescence-associated secretory phenotype that functioned through NFκB signaling to influence changes in the tumor microenvironment, such as recruitment of Ly6G+ inflammatory cells and vessel formation. [Cell Death Differ] Full Article The authors aimed to identify key signaling pathways specific for anaplastic thyroid carcinoma (ATC)-CSCs. The siRNA library targeting 719 kinases was used in a sphere formation assay and cell survival assay using ATC cell lines to select target molecules specific for the CSC properties. [Thyroid] Abstract Researchers showed that the IL-6/STAT3 inflammatory signaling axis induced the deacetylation of FRA1 at the Lys-116 residue located within its DNA-binding domain. The HDAC6 deacetylase underlies this key modification leading to the increase of FRA1 transcriptional activity, the subsequent transactivation of NANOG expression, and the acquisition of stem-like cellular features. [Oncogene] Full Article The authors found that prolonged transforming growth factor-β (TGF-β) exposure, mimicking the state of in vivo carcinomas, promoted stable epithelial-to-mesenchymal transition (EMT) in mammary epithelial and carcinoma cells, in contrast to the reversible EMT induced by a shorter exposure. [Sci Signal] Full Article miR-873/PD-L1 Axis Regulates the Stemness of Breast Cancer Cells PD-L1 expression was positively correlated with the expression of stemness markers, and overexpression of PD-L1 contributed to chemoresistance and stemness-like properties in breast cancer cells via activating PI3K/Akt and ERK1/2 pathways. [EBioMedicine] Full Article Scientists showed for the first time that BCL-3 acted as a co-activator of β-catenin/TCF-mediated transcriptional activity in colorectal cancer cells and that this interaction was important for Wnt-regulated intestinal stem cell gene expression. [Dis Model Mech] Abstract | Full Article Investigators found that a commercially available culture medium for maintenance of ES cells and induced pluripotent stem cells, mTeSR1, effectively prevented spontaneous differentiation by CD13+CD166‐ cells to CD13‐CD166+ cells and therefore maintained the CSC population in Li‐7 cell cultures. [Cancer Sci] Abstract The levels of miR-451 were tested in colon cancer cell lines. Multiple functional and immunological assays were performed to analyze miR-451 induced growth changes in vitro and downstream effects on target proteins. [Gene] Abstract Subscribe to one of our other 19 science newsletters such as Neural Cell News & Hematopoiesis News. | |
| |
REVIEWSThe authors first summarize the current understanding of the regulation of self‐renewal by Krüppel‐like factor (KLF) proteins in embryonic stem cells through a KLF circuitry and then delve into the potential function of KLF4 in normal hematopoietic stem cells and its emerging role in leukemia‐initiating cells from pediatric patients with T‐cell acute lymphoblastic leukemia via repression of the mitogen‐activated protein kinase 7 pathway. [Stem Cells Transl Med] Full Article Visit our reviews page to see a complete list of reviews in the cancer stem cell research field. | |
| |
INDUSTRY NEWSThe Centre for the Commercialization of Antibodies and Biologics (CCAB) announced a license agreement with Empirica Therapeutics Inc. aimed at developing new treatments for one of the deadliest forms of brain cancer, glioblastoma. [Centre for the Commercialization of Antibodies and Biologics] Press Release Agios Pharmaceuticals, Inc. announced that the FDA has accepted the company’s supplemental New Drug Application for TIBSOVO® for the treatment of patients with newly diagnosed acute myeloid leukemia with an isocitrate dehydrogenase 1 (IDH1) mutation who are not eligible for standard therapy. [Agios Pharmaceuticals, Inc.] Press Release | |
| |
POLICY NEWSHigh-Profile Subscription Journals Critique Plan S Publishers of highly selective scholarly journals — including Nature and Science — say that they cannot comply with Plan S, a European-led initiative that mandates free access to research results on publication from 2020, unless its rules are changed. [Nature News] Editorial Data Sharing Will Be a Major Thrust of Trump’s $500 Million Childhood Cancer Plan President Donald Trump’s proposal in his State of the Union address to spend $500 million over 10 years on pediatric cancer research will begin in 2020 with a focus on sharing patients’ data, federal officials say. That plan is getting a mixed response from researchers and patient advocates, who also worry that the initiative will come at expense of other parts of the National Cancer Institute’s budget. [ScienceInsider] Editorial
| |
EVENTSNEW Gordon Research Conference: Mammary Gland Biology Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESPostdoctoral Scholarship – Glioblastoma Stem Cell Research (Lund University) Postdoctoral Positions – Stem Cell and Cancer Biology (Columbia University Irving Medical Center) Postdoctoral Position – Ovarian Cancer Stem Cells (University of Minnesota) Postdoctoral Position – Stem Cell Aging and Cancer (University of California – San Francisco) Postdoctoral Fellow – Epigenetics and Cancer (The University of Texas MD Anderson Cancer Center) Postdoctoral Associate – Pediatrics, Cancer Biology (University of Massachusetts) Postdoctoral Position – Colon Cancer (Vanderbilt University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|